Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 plus cisplatin chemoradiotherapy in locally advanced head and neck cancer
NL-OMON33661Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of r-(-)-gossypol acetic acid in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Tolerability and feasible administrable dose of AT-101 with chemoradiotherapy. Planned start Jan 2009; status: not yet recruiting.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON33661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33661.